Citing significant, unresolved safety risks, a total lack of robust human clinical efficacy data, and grave concerns over immunogenicity and peptide-related impurities, the FDA officially designated 19 of the most popular therapeutic peptidesexplicitly including BPC-157, TB-500 (Thymosin beta-4 fragment), and injectable GHK-Cuas Category 2 bulk drug substances
In vitro and animal studies have found that lipoic acid exhibits immunomodulatory properties through mechanisms that stimulate the production of cyclic AMP (cAMP) (90, 91) a central regulator of innate immune functions and inhibits the migration of immune cells into the brain and spinal cord (92), possibly by decreasing endothelial expression of cell adhesion molecules, inhibiting expression of enzymes like matrix metalloproteinases (MMP), and/or reducing the permeability of the blood-brain barrier (87, 89, 93, 94)
See the full dosage guide
The FDA has not approved them for medical treatment
When GSH is depleted or when oxidised GSSG accumulates, cells experience damage that accelerates ageing, inflammation, and chronic disease
"Alterations in glutathione levels in Parkinson's disease." Ann Neurol
